Table 2.
Sexual behaviour and vaccine uptake of the study participants stratified by HPV16/HPV18 positivity.
| Total | HPV16/HPV18-negative | HPV16/HPV18-positive | p-value | |
|---|---|---|---|---|
| N = 1,226 | N = 1,132 | N = 94 | ||
| Current relationship | 0.046 | |||
| No | 354 (28.9%) | 316 (27.9%) | 38 (40.4%) | |
| Yes | 846 (69.0%) | 793 (70.1%) | 53 (56.4%) | |
| Not specified | 2 (0.2%) | 2 (0.2%) | 0 (0.0%) | |
| Missing | 24 (2.0%) | 21 (1.9%) | 3 (3.2%) | |
| Lifetime number sexual partners (mean & IQR) | 4 (1–7) | 3 (1–7) | 9 (5–15) | <0.001 |
| Lifetime number male sexual partners (mean & IQR) | 4 (2–7) | 3 (2–6) | 8 (4–14) | <0.001 |
| Lifetime number female sexual partners (mean & IQR) | 0 (0–0) | 0 (0–0) | 0 (0–1) | 0.026 |
| Number sexual partners 12 months | <0.001 | |||
| 0 | 238 (19.4%) | 231 (20.4%) | 7 (7.4%) | |
| 1 | 667 (54.4%) | 638 (56.4%) | 29 (30.9%) | |
| 2 | 144 (11.7%) | 127 (11.2%) | 17 (18.1%) | |
| 3–5 | 119 (9.7%) | 93 (8.2%) | 26 (27.7%) | |
| >5 | 30 (2.4%) | 18 (1.6%) | 12 (12.8%) | |
| Not specified | 4 (0.3%) | 4 (0.4%) | 0 (0.0%) | |
| Missing | 24 (2.0%) | 21 (1.9%) | 3 (3.2%) | |
| Age sexual debut | 0.13 | |||
| No sexual intercourse yet | 60 (4.9%) | 60 (5.3%) | 0 (0.0%) | |
| <13 years | 6 (0.5%) | 6 (0.5%) | 0 (0.0%) | |
| 13 years | 49 (4.0%) | 44 (3.9%) | 5 (5.3%) | |
| 14 years | 139 (11.3%) | 122 (10.8%) | 17 (18.1%) | |
| 15 Years | 178 (14.5%) | 168 (14.8%) | 10 (10.6%) | |
| 16 years | 247 (20.1%) | 225 (19.9%) | 22 (23.4%) | |
| 17 years | 179 (14.6%) | 166 (14.7%) | 13 (13.8%) | |
| >17 years | 342 (27.9%) | 318 (28.1%) | 24 (25.5%) | |
| Missing | 26 (2.1%) | 23 (2.0%) | 3 (3.2%) | |
| Condom use in current relationship | 0.013 | |||
| No | 523 (42.7%) | 469 (41.4%) | 54 (57.4%) | |
| Yes | 629 (51.3%) | 595 (52.6%) | 34 (36.2%) | |
| Not specified | 50 (4.1%) | 47 (4.2%) | 3 (3.2%) | |
| Missing | 24 (2.0%) | 21 (1.9%) | 3 (3.2%) | |
| Condom use with new partners | 0.32 | |||
| No | 87 (7.1%) | 82 (7.2%) | 5 (5.3%) | |
| Yes | 981 (80.0%) | 901 (79.6%) | 80 (85.1%) | |
| Not specified | 134 (10.9%) | 128 (11.3%) | 6 (6.4%) | |
| Missing | 24 (2.0%) | 21 (1.9%) | 3 (3.2%) | |
| Oral contraceptives | 0.45 | |||
| No | 140 (11.4%) | 132 (11.7%) | 8 (8.5%) | |
| Yes | 1,050 (85.6%) | 967 (85.4%) | 83 (88.3%) | |
| Not specified | 12 (1.0%) | 12 (1.1%) | 0 (0.0%) | |
| Missing | 24 (2.0%) | 21 (1.9%) | 3 (3.2%) | |
| HPV vaccination (at least one dose) | 0.037 | |||
| No | 377 (30.8%) | 338 (29.9%) | 39 (41.5%) | |
| Yes | 757 (61.7%) | 712 (62.9%) | 45 (47.9%) | |
| I don’t know | 60 (4.9%) | 53 (4.7%) | 7 (7.4%) | |
| Missing | 32 (2.6%) | 29 (2.6%) | 3 (3.2%) | |
| Cervarix | 0.69 | |||
| No | 1,163 (94.9%) | 1,073 (94.8%) | 90 (95.7%) | |
| Yes | 63 (5.1%) | 59 (5.2%) | 4 (4.3%) | |
| Gardasil | 0.004 | |||
| No | 594 (48.5%) | 535 (47.3%) | 59 (62.8%) | |
| Yes | 632 (51.5%) | 597 (52.7%) | 35 (37.2%) | |
| Gardasil9 | 0.39 | |||
| No | 1,217 (99.3%) | 1,123 (99.2%) | 94 (100.0%) | |
| Yes | 9 (0.7%) | 9 (0.8%) | 0 (0.0%) | |
| Vaccination (recommended scheme) | 0.022 | |||
| No | 377 (30.8%) | 338 (29.9%) | 39 (41.5%) | |
| Yes | 348 (28.4%) | 331 (29.2%) | 17 (18.1%) | |
| Missing | 501 (40.9%) | 463 (40.9%) | 38 (40.4%) |
Statistically significant p-values in bold.